Skip to main content
ChemoMetec logo

ChemoMetec — Investor Relations & Filings

Ticker · CHEMM ISIN · DK0060055861 LEI · 213800533NBKECGONO68 CO Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2024-04-12 Earnings Release
Country DK Denmark
Listing CO CHEMM

About ChemoMetec

https://chemometec.com

ChemoMetec is a global manufacturer specializing in high-precision automated cell counting and analysis instrumentation. The company develops and produces a range of advanced image cytometers and cell density analyzers, including the NucleoCounter® and XcytoMatic® series. These systems provide consistent, reproducible, and accurate cell count and viability data for a wide range of cell types. Key technologies include fluorescence microscopy, which enables trypan blue-free analysis, and specialized consumables designed to minimize human error. ChemoMetec's instruments are designed for regulated environments, offering software solutions compliant with FDA 21 CFR Part 11 and supporting Good Manufacturing Practice (GMP) workflows. The company serves customers in the biotechnology, pharmaceutical, and academic sectors, with applications in cell and gene therapy, cancer research, and bioprocessing.

Recent filings

Filing Released Lang Actions
Earnings Release 2024
Earnings Release Classification · 1% confidence The document is a short announcement (2494 characters) titled "Præcisering af forventningerne til omsætning og lavere end forventet driftsresultat i regnskabsåret 2023/24" (Clarification of revenue expectations and lower than expected operating result for the fiscal year 2023/24). It provides preliminary figures and updates guidance for the full year, but crucially, it states that the final figures will be published later ("Endelige tal for tredje kvartal 2023/24... vil fremgå af periodemeddelelsen for tredje kvartal 2023/24, der offentliggøres den 8. maj 2024"). Furthermore, it includes an attachment link labeled "Meddelelse 261 - Ændring af forventninger til 2023-24". This structure—a brief announcement detailing a change in outlook and pointing to a future, more detailed report—fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since the content is specifically about announcing a change in financial guidance/expectations, it is closely related to earnings/financial reporting, but because it is an announcement *about* the results/outlook rather than the full report itself (which is coming later), RPA is the most appropriate classification based on the 'MENU VS MEAL' rule, as it announces the publication of future detailed results (the Q3 report). However, given the content is a direct financial guidance update, it is also very close to an Earnings Release (ER) or Interim Report (IR) context. Since it is a formal announcement (Meddelelse NR. 261) updating guidance, and it explicitly points to the future release of the full quarterly report, it functions as a pre-release or a specific financial update announcement. Given the options, and the fact that it is a formal notification of financial expectation changes, it is best classified as an Earnings Release (ER) which often includes guidance updates, or RPA if it were purely announcing the publication of another document. Since it contains the core financial updates (revenue and EBITDA guidance change), ER is a strong candidate. However, if we strictly follow the rule that if it's short and points to a future report, it's RPA, we must consider that. The document itself *is* the update on expectations, not just an announcement that the Q3 report is coming. It is a direct financial update. Let's re-evaluate: ER is for the initial announcement of periodical financial results (key highlights). This document *is* the highlight/update on the full year expectations based on preliminary Q3 data. This aligns well with ER. If it were just saying 'The Q3 report will be released on May 8th', it would be RPA. Since it contains the actual guidance revision, ER is better than RPA. 9M 2024
2024-04-12 Danish
Præcisering af forventningerne til omsætning og lavere end forventet driftsresultat i regnskabsåret 2023/24
Earnings Release Classification · 1% confidence The document is a short announcement (1850 characters) from ChemoMetec regarding an adjustment to their financial guidance for the 2023/24 fiscal year. It provides preliminary revenue and EBITDA figures but explicitly states that final figures will be included in the upcoming interim report to be published on 8 May 2024. Since this is an initial announcement of financial highlights and guidance updates rather than the full interim report itself, it falls under the Earnings Release category. 9M 2024
2024-04-12 English
Præcisering af forventningerne til omsætning og lavere end forventet driftsresultat i regnskabsåret 2023/24
Regulatory Filings Classification · 1% confidence The document is a short announcement (1724 characters) from ChemoMetec regarding a revision of their financial guidance (revenue and EBITDA expectations) for the 2023/24 fiscal year. It explicitly states that the final figures for the third quarter will be published in a separate report on May 8, 2024. Since this is an initial announcement of financial results/guidance updates rather than the full report itself, and it does not fit into specific categories like M&A or dividends, it is classified as a Regulatory Filing (RNS).
2024-04-12 Danish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 1% confidence The document is titled "Storaktionærmeddelelse" (Major Shareholder Notification) and explicitly states that BlackRock, Inc. has increased its holding of voting rights above the 10% threshold as per the Danish Capital Markets Act (§ 30 and § 38). This directly corresponds to the definition of a notification of changes in significant share ownership levels crossing thresholds. Therefore, the correct classification is Major Shareholding Notification (MRQ). The document is short and is a direct notification, not an announcement of a larger report.
2024-04-10 Danish
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'Major shareholder announcement – BlackRock, Inc.' and details that BlackRock, Inc. has increased its holding of voting rights in ChemoMetec A/S above the 10% threshold, citing specific sections of the Capital Markets Act. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds.
2024-04-10 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'Major shareholder announcement' and details a change in shareholding percentage by Swedbank Robur Fonder AB, specifically noting that their holding decreased below the 5% threshold as required by Section 38 of the Danish Capital Markets Act. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2024-04-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.